clinical trial · NCT07571200
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Eli Lilly and Company·phase1·not yet recruiting·n = 32
Amyotrophic Lateral SclerosisLY4256984
brief summary
Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group. The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.
started
May 1, 2026
primary completion
Jun 1, 2029
completion
Jun 1, 2029
last updated
May 6, 2026
official title
A Master Protocol for Open-Label Extension Studies to Evaluate the Long-Term Safety and Tolerability of Interventions in Various Stages of Clinical Development in Participants With Amyotrophic Lateral Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol